Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
Human serum albumin (HSA) did not affect oritavancin MICs against non-vancomycin-intermediate Staphylococcus aureus (non-VISA) strains. In time-kill assays, oritavancin bactericidal activity in the presence of HSA was significantly more rapid than comparators against non-VISA strains. HSA increased oritavancin MICs by 4-fold for VISA strains, reflective of reduced oritavancin activity in time-kill assays with HSA.
Arhin
Francis F
FF
Anti-Infective Unit, The Medicines Company, St. Laurent, Quebec H4S 2A1, Canada. farhin.arhin@themedco.com
McKay
Geoffrey A
GA
Beaulieu
Sylvain
S
Sarmiento
Ingrid
I
Parr
Thomas R
TR
Moeck
Gregory
G
D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D006020:Glycopeptides / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D012709:Serum Albumin; D013211:Staphylococcus aureus / Q000187:drug effects*; D013997:Time Factors; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D012709:Serum Albumin; C100708:oritavancin; D014640:Vancomycin